Halozyme Therapeutics Files 8-K on Financials
Ticker: HALO · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
Related Tickers: HALO
TL;DR
HALO filed an 8-K on Jan 8, 2025, reporting on financials. No major news yet.
AI Summary
On January 8, 2025, Halozyme Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Halozyme Therapeutics is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting on financial condition and results of operations, with no immediately apparent negative or positive material events disclosed in the provided text.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Registrant
- January 8, 2025 (date) — Date of Report
- 001-32335 (other) — Commission File Number
- Delaware (other) — State of Incorporation
- 88-0488686 (other) — I.R.S. Employer Identification No.
- 12390 El Camino Real (other) — Business Address
- San Diego (other) — City
- 92130 (other) — Zip Code
- California (other) — State
- ( 858 ) 794-8889 (other) — Business Phone
FAQ
What is the primary purpose of this 8-K filing by Halozyme Therapeutics?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on January 8, 2025.
What is Halozyme Therapeutics, Inc.'s Commission File Number?
Halozyme Therapeutics, Inc.'s Commission File Number is 001-32335.
In which state was Halozyme Therapeutics, Inc. incorporated?
Halozyme Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Halozyme Therapeutics, Inc.?
The principal executive office address for Halozyme Therapeutics, Inc. is 12390 El Camino Real, San Diego, California, 92130.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-01-08 08:00:20
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market
Filing Documents
- halo-20250108.htm (8-K) — 32KB
- ex991financialguidance.htm (EX-99.1) — 57KB
- halo-20250108_g1.jpg (GRAPHIC) — 15KB
- halozymea23a.jpg (GRAPHIC) — 685KB
- 0001159036-25-000003.txt ( ) — 1170KB
- halo-20250108.xsd (EX-101.SCH) — 2KB
- halo-20250108_lab.xml (EX-101.LAB) — 21KB
- halo-20250108_pre.xml (EX-101.PRE) — 12KB
- halo-20250108_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 8, 2025, Halozyme Therapeutics, Inc., a Delaware corporation (the "Company") issued a press release containing information related to the Company's 2025 financial guidance (the "Press Release"). The Press Release included a summary of preliminary, unaudited estimates regarding the Company's financial results for the year ended December 31, 2024 (the "Preliminary 2024 Estimates"). A copy of the Press Release is attached as Exhibit 99.1. The Press Release and Preliminary 2024 Estimates are furnished under Item 2.02 of this report and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release dated January 8, 2025 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Halozyme Therapeutics, Inc. (Registrant) Dated: January 8, 2025 By: /s/ Nicole LaBrosse Nicole LaBrosse Senior Vice President, Chief Financial Officer